HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD (600671.SS)

Wednesday

12:56 AM

Thesis: Recent contract wins and regulatory approvals are expected to drive revenue growth, shifting sentiment positively.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$217M	$211M
Rev. Growth	+78.4%	-3.1%
EPS	$0.13	$0.14
EPS Growth	+142%	+7.7%
P/E	159.3×	147.9×

What’s Driving the Stock

1The company has secured a 5-year contract with a major hospital network in Zhejiang province, expected to increase revenue by 15% annually.
2Recent regulatory approval for a new cardiovascular drug could lead to a 20% increase in market share within the next year.
3The company is exploring partnerships with biotech firms to expand its pipeline, potentially increasing R&D efficiency by 30%.
4Increased demand for generics due to rising healthcare costs
5Focus on cardiovascular health as a growing therapeutic area
6Regulatory approvals for new generic drugs
7Market share gains in cardiovascular drug segments
8Pricing pressures from government healthcare policies

FY2025 Snapshot

Revenue: $211M
Rev. Growth: -3.1%
Gross Margin: 39.1%
Op. Margin: 6.6%
Net Margin: 8.4%
Net Income: $18M
NI Growth: +15.6%
EPS: $0.14
1Y Return: +37.7%

My Notes

"Management emphasized, 'Our strategic partnerships and new product approvals are set to redefine our growth trajectory.'"
Moat: The company's established distribution network and R&D capabilities provide a moderate level of competitive advantage.
value - Investors may be drawn to the company's strong ROE and net margins despite recent revenue declines.
Interest rates affect financing costs for R&D and expansion, which can impact profitability and valuation multiples.
Watch on earnings: Regulatory approval timelines for new drugs, Market share in key therapeutic areas, Changes in government healthcare policies.

One Sentence Summary:

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd: the setup is constructive — the company has secured a 5-year contract with a major hospital network in zhejiang province, expected to increase revenue by 15% annually.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.